LU92348I2 - Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV) - Google Patents

Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV)

Info

Publication number
LU92348I2
LU92348I2 LU92348C LU92348C LU92348I2 LU 92348 I2 LU92348 I2 LU 92348I2 LU 92348 C LU92348 C LU 92348C LU 92348 C LU92348 C LU 92348C LU 92348 I2 LU92348 I2 LU 92348I2
Authority
LU
Luxembourg
Prior art keywords
wnv
equip
strain
pharmaceutically acceptable
west nile
Prior art date
Application number
LU92348C
Other languages
English (en)
French (fr)
Other versions
LU92348I9 (instruction
Original Assignee
Zoetis W Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W Llc filed Critical Zoetis W Llc
Publication of LU92348I2 publication Critical patent/LU92348I2/xx
Publication of LU92348I9 publication Critical patent/LU92348I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LU92348C 2001-07-27 2014-01-06 Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV) LU92348I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27

Publications (2)

Publication Number Publication Date
LU92348I2 true LU92348I2 (fr) 2014-09-22
LU92348I9 LU92348I9 (instruction) 2019-01-02

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92348C LU92348I2 (fr) 2001-07-27 2014-01-06 Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV)

Country Status (24)

Country Link
US (8) US7153513B2 (instruction)
EP (3) EP1427444B1 (instruction)
JP (2) JP4718778B2 (instruction)
KR (2) KR20090053967A (instruction)
CN (2) CN1273189C (instruction)
AU (1) AU2002365244B2 (instruction)
BE (1) BE2014C006I2 (instruction)
BR (1) BRPI0211492B1 (instruction)
CA (1) CA2452545C (instruction)
CY (1) CY2014010I2 (instruction)
DK (1) DK1427444T3 (instruction)
ES (1) ES2435095T3 (instruction)
FR (1) FR14C0016I2 (instruction)
HR (1) HRP20040195B1 (instruction)
HU (2) HU228690B1 (instruction)
LU (1) LU92348I2 (instruction)
ME (1) ME00491B (instruction)
MX (1) MXPA04000680A (instruction)
NZ (3) NZ531265A (instruction)
PL (2) PL212212B1 (instruction)
PT (1) PT1427444E (instruction)
RS (1) RS53184B (instruction)
WO (1) WO2003061555A2 (instruction)
ZA (1) ZA200401596B (instruction)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CN1273189C (zh) * 2001-07-27 2006-09-06 惠氏公司 西尼罗河疫苗
EP1664786B1 (en) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
CA2612047C (en) 2005-06-24 2015-05-12 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
CA2626489C (en) * 2005-10-19 2020-10-27 University Of Florida Research Foundation, Inc Materials and methods for respiratory disease control in canines
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
CA2646623A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
BRPI0820341B1 (pt) * 2007-11-06 2021-11-09 Zoetis Services Llc Composição imunogênica para uso na proteção de um animal contra uma doença associada a uma cepa virulenta de mycoplasma hyopneumoniae
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
CA2732035A1 (en) * 2008-07-30 2010-02-04 University Of Kentucky Research Foundation Equine disease model for herpesvirus neurologic disease and uses thereof
SG193821A1 (en) * 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
EP2485725A2 (en) * 2009-10-07 2012-08-15 Wyeth LLC Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
NZ614147A (en) 2011-03-14 2015-08-28 Boehringer Ingelheim Vetmed Equine rhinitis vaccine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
CN108079290A (zh) * 2013-05-14 2018-05-29 硕腾服务有限责任公司 包含免疫刺激性寡核苷酸的新颖疫苗组合物
CN105530956A (zh) * 2013-09-05 2016-04-27 硕腾服务有限责任公司 Hendra和Nipah病毒G糖蛋白免疫原性组合物
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
ATE365049T1 (de) * 1994-05-10 2007-07-15 Wyeth Corp Abgeänderter, verbesserter brsv lebend- impfstoff
BR9910830A (pt) 1998-06-04 2001-02-13 Us Gov Health & Human Serv Vacinas de ácido nucléico para prevenção de infecção flavivìrus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2004510714A (ja) * 2000-10-04 2004-04-08 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア フラビウイルス及びペスチウイルス由来のキャプシド蛋白質を使用する組成物及び方法
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
CA2440593A1 (en) * 2001-03-12 2002-09-19 Yale University Compositions and methods comprising west nile virus polypeptides
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
CN1273189C (zh) * 2001-07-27 2006-09-06 惠氏公司 西尼罗河疫苗
AU2003263853A1 (en) 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
HU228690B1 (en) 2013-05-28
KR20040028952A (ko) 2004-04-03
US20070231350A1 (en) 2007-10-04
NZ570270A (en) 2010-08-27
PL220846B1 (pl) 2016-01-29
PL368535A1 (en) 2005-04-04
HUS1300055I1 (hu) 2016-08-29
PL398575A1 (pl) 2012-06-18
US20070166324A1 (en) 2007-07-19
EP2281572A1 (en) 2011-02-09
JP2005515236A (ja) 2005-05-26
CY2014010I2 (el) 2024-02-16
MXPA04000680A (es) 2004-04-05
US20070166326A1 (en) 2007-07-19
HRP20040195B1 (hr) 2014-07-18
ES2435095T3 (es) 2013-12-18
CN1535157A (zh) 2004-10-06
PL212212B1 (pl) 2012-08-31
YU8004A (sh) 2006-08-17
HUP0401606A2 (hu) 2004-11-29
CN1935258A (zh) 2007-03-28
BE2014C006I2 (instruction) 2021-02-04
JP4718778B2 (ja) 2011-07-06
NZ531265A (en) 2008-08-29
JP2011057692A (ja) 2011-03-24
WO2003061555A2 (en) 2003-07-31
CA2452545C (en) 2015-06-09
HRP20040195A2 (en) 2004-08-31
BR0211492A (pt) 2004-08-17
EP2283858A3 (en) 2011-03-23
FR14C0016I2 (fr) 2015-07-24
BRPI0211492B1 (pt) 2016-06-21
CY2014010I1 (el) 2020-05-29
US20030091595A1 (en) 2003-05-15
US7648706B2 (en) 2010-01-19
AU2002365244B2 (en) 2007-12-06
US7648705B2 (en) 2010-01-19
ZA200401596B (en) 2005-07-27
NZ553165A (en) 2008-09-26
HUP0401606A3 (en) 2005-02-28
RS53184B (sr) 2014-06-30
EP1427444A4 (en) 2008-01-02
WO2003061555A3 (en) 2004-04-15
LU92348I9 (instruction) 2019-01-02
KR20090053967A (ko) 2009-05-28
US20070166325A1 (en) 2007-07-19
US20070166802A1 (en) 2007-07-19
US20070178119A1 (en) 2007-08-02
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
DK1427444T3 (da) 2013-11-04
CA2452545A1 (en) 2003-07-31
PT1427444E (pt) 2013-11-19
CN1935258B (zh) 2013-04-03
FR14C0016I1 (instruction) 2014-03-28
EP2283858A2 (en) 2011-02-16
HK1066470A1 (en) 2005-03-24
CN1273189C (zh) 2006-09-06
US20070231349A1 (en) 2007-10-04
US7445787B2 (en) 2008-11-04
ME00491B (me) 2011-10-10
US7153513B2 (en) 2006-12-26

Similar Documents

Publication Publication Date Title
LU92348I2 (fr) Virus West Nile inactivé, souche VM-2 et ses dérivés pharmaceutiquement acceptables (EQUIP WNV)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
NO20033726L (no) Xantin-derivater, fremstilling og anvendelse derav som et medikament
NO20035298D0 (no) CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
ZA200603158B (en) Immunogenic composition and method of developing a vaccine based on psoralen inactivated HIV
DK1419150T3 (da) 1-Phenylsulfonyl-1,3-dihydro-2H-indol-2-on-derivater, deres fremstilling og deres terapeutiske anvendelse
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
DK1337529T3 (da) Heterocyclylalkylpiperidinderivater, deres fremstilling og præparater indeholdende dem
NO20030596D0 (no) Benzimidazolderivater, deres fremstilling og terapeutiske anvendelse
DK1445252T3 (da) Sulfonamid-derivater, deres fremstilling og anvendelse som medikamenter
NO20010028D0 (no) Benzimidazoler, deres fremstilling og anvendelse som legemidler
LU91251I2 (fr) Vaccin à rotavirus (vivant) et ses dérivés pharmaceutiquement acceptables (ROTARIXr)
DE60209929D1 (de) Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
NO20014270L (no) Pyridopyranoazepinderivater, deres fremstilling og terapeutisk anvendelse
NO20031838D0 (no) Benzokazinonderivater, deres fremstilling og anvendelse
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
NO20040995L (no) Subenhetsvaksine for smittsom bukspyttkjertel-nekrosevirus
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)